Optima WES Clinician Information

There are three possible outcomes that may result from your exome analysis:

Some tests may also identify secondary findings, which are genetic changes unrelated to the original reason for testing but associated with conditions for which medical management, screening, or treatment options are available, as recommended by the American College of Medical Genetics and Genomics (ACMG). Receiving these results is optional.

Interpretation of WES results is phenotype-dependent and should be integrated with the indication for testing, inheritance model, family structure, and any prior molecular or cytogenetic data. The strongest clinical utility arises when the molecular finding is concordant with the observed phenotype and supported by inheritance data, functional evidence, or established gene-disease validity. Conversely, discordant or weakly supported findings require caution, particularly in prenatal settings where phenotypic information may be incomplete and the downstream clinical implications are time sensitive. Trio analysis and careful pretest phenotyping improve both the accuracy and actionability of interpretation.

For clinician interpretation, it is useful to distinguish analytic performance from clinical yield. Analytic sensitivity refers to the assay’s ability to detect a variant when it is truly present; analytic specificity refers to the rate at which called variants are truly absent when not present. Coverage metrics, such as mean depth at ~100X and the proportion of targeted bases covered at ≥20X, describe how completely the exome was technically assessed. Precision reflects repeatability and reproducibility of variant detection across runs or operators. By contrast, diagnostic yield is a clinical measure: the proportion of tested cases in which the assay identifies a causative or likely causative molecular diagnosis. Reported WES yields vary by indication and phenotype severity, commonly around 20–50% in suspected Mendelian disease and higher in selected severe early-onset disorders.

The clinical scope of WES includes evaluation of patients with suspected monogenic disease across neurology, neurodevelopment, congenital anomalies, metabolic disease, multisystem disorders, and other heterogeneous rare-disease presentations. Postnatally, WES is supported by guideline-level recommendations in children with congenital anomalies, developmental delay, or intellectual disability, particularly when no single diagnosis is strongly suspected. Prenatally, exome sequencing is considered primarily in fetuses with one or more structural anomalies after standard diagnostic evaluation has been performed or when the phenotype suggests an underlying monogenic disorder that is not adequately addressed by conventional testing alone.

Clinically deployed WES typically uses targeted exome capture followed by high-throughput sequencing and bioinformatic analysis of coding exons and splice-adjacent regions, and exome-based deletion/duplication analysis. Laboratory interpretation is generally performed within a phenotype-driven framework, using curated disease-gene knowledgebases, inheritance filtering, population databases, and standardized variant-classification criteria. The quality of the final result depends not only on sequencing depth and informatics, but also on the completeness of phenotypic data supplied by the ordering clinician.

Clinical performance is indication-dependent and should be discussed in terms of both analytic validity and real-world diagnostic yield. One clinical provider source reports that WES can provide a definitive diagnosis in approximately 20–50% of patients with suspected Mendelian disorders, while another reports typical diagnosis rates of roughly 20–60% depending on specialty and phenotype, with the highest rates in severe early-onset disease. Analytically, validated exome workflows from provider-published materials report high sequencing uniformity, high proportions of targeted bases covered to clinically usable depth, and very high specificity for single-nucleotide variants, with somewhat lower but still strong performance for small indels. These metrics support clinical use, but they do not eliminate blind spots inherent to exome-based testing.

WES is not a universal assay for all classes of genomic variation. Depending on the platform and laboratory design, it may have limited ability to detect repeat expansions, balanced translocations, complex inversions, low-level mosaicism, deep intronic or regulatory variants outside targeted regions, methylation abnormalities, and some structural rearrangements. In addition, negative or inconclusive results are more likely when the phenotype is poorly characterized, when the true mechanism is non-exomic, or when the relevant gene-disease association is not yet established. WES is therefore not the preferred stand-alone test when the differential strongly favors a variant type or mechanism better addressed by another modality.

Additional practical limitations include incomplete phenotyping, limited family samples, incidental or secondary findings, and the dynamic nature of gene-disease knowledge. Prenatally, interpretation is further complicated by the fact that fetal phenotypes may be incomplete on ultrasound, evolving over gestation, or insufficiently specific for strong genotype-phenotype matching. Laboratories and clinicians should therefore set expectations appropriately: WES may clarify prognosis and recurrence risk, but it may also yield uncertain findings (VUS) that require postnatal reassessment or reanalysis as new phenotypic or scientific information emerges. Pretest counseling and careful consent are especially important when discussing the possibility of uncertain or secondary findings.

Clinical WES reports classify variants according to ACMG/AMP-aligned frameworks and correlate prioritized findings with the supplied phenotype and inheritance model. A clinician-facing report should clearly distinguish diagnostic findings from candidate findings, VUS, and secondary findings, and should state whether the identified variant fully explains, partially explains, or does not adequately explain the presentation. Good reports also summarize relevant assay limitations, inheritance implications, and any recommended follow-up, such as parental testing, confirmatory studies, or phenotype-directed reassessment. This reporting structure helps ensure that molecular findings are interpreted within an explicitly clinical context rather than as decontextualized sequence data.

In routine practice, WES is most effective when integrated after a focused clinical genetics work-up but before prolonged cascades of low-yield sequential testing. Typical workflow includes referral based on a suspected monogenic phenotype, detailed phenotypic documentation, consent regarding primary and optional secondary findings, collection of proband and ideally parental samples, laboratory sequencing and interpretation, and post-analytic review in the context of the patient’s evolving clinical picture. Prenatal workflows add specimen-specific constraints, and one provider notes that prenatal exome testing for ongoing pregnancies requires cultured cells, with reported turnaround times in the range of approximately 4-6 weeks in that service model.

A clinically useful WES service is not defined by breadth alone but by how effectively it supports medical decision-making. This includes robust assay validation, consistent sequencing quality, phenotype-driven analysis, transparent variant classification, and reporting that is actionable for the referring clinician. Family-based testing options, exome-based CNV analysis, rapid pathways for urgent cases, and support for reinterpretation can all increase utility in real-world clinical settings. For this reason, the most effective WES offerings are those designed around diagnostic performance and interpretability rather than simple assay expansiveness.

The clinical value of WES lies in its ability to shorten the diagnostic odyssey, improve etiologic diagnosis in genetically heterogeneous disorders, and provide information that can alter management, surveillance, prognosis, reproductive counseling, and family testing. Current professional guidance supports earlier use of exome (WES) or genome (WGS) sequencing in selected pediatric indications because of higher diagnostic yield relative to older stepwise approaches. In prenatal medicine, exome sequencing can add diagnostic information when fetal anomalies remain unexplained after standard testing, thereby improving counseling about prognosis, recurrence risk, and pregnancy or neonatal care planning. Its value is greatest when ordered for the right indication and interpreted by a multidisciplinary team familiar with genomic uncertainty.